Matthijs L Becker - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Matthijs L Becker

Showing results (41-50 of 50) with videos related to

Pageof 5

Sort By:

You have reached the last page of results.This site can display upto 50 results.

Pharmacy Practice|January 15, 2019

Frequency of occurrence of medication discrepancies and associated risk factors in cases of acute hospital admissionCharlotte D Van Der Luit, Iris R De Jong, Marieke M Ebbens, et al.

Pharmacogenetics and Genomics|June 14, 2008

Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylureaMatthijs L Becker, Albert-Jan L H J Aarnoudse, Christopher Newton-Cheh, et al.

Pharmacy World & Science : PWS|December 26, 2006

Determinants of potential drug-drug interaction associated dispensing in community pharmacies in the NetherlandsMatthijs L Becker, Peter W J Caspers, Marjon Kallewaard, et al.

Pharmacology Research & Perspectives|July 24, 2021

Switching TNFα inhibitors: Patterns and determinantsRosanne W Meijboom, Helga Gardarsdottir, Matthijs L Becker, et al.

International Journal of Clinical Pharmacy|July 28, 2018

Development of a risk model for predicting QTc interval prolongation in patients using QTc-prolonging drugsAnita N Bindraban, José Rolvink, Florine A Berger, et al.

British Journal of Clinical Pharmacology|October 24, 2017

QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factorsFlorine A Berger, Nico Monadian, Natasja M S de Groot, et al.

Pharmacogenetics and Genomics|November 23, 2013

The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam StudyCatherine E de Keyser, Bas J M Peters, Matthijs L Becker, et al.

European Journal of Clinical Pharmacology|November 24, 2017

Risk factors for QTc interval prolongationCharlotte P M Heemskerk, Marieke Pereboom, Karlijn van Stralen, et al.

European Journal of Clinical Pharmacology|July 28, 2021

Unintentional guideline deviations in hospitalized patients with two or more antithrombotic agents: an intervention studyRenate C A E van Uden, Marcel P H van den Broek, Ilse Houtenbos, et al.

Thrombosis Research|February 20, 2024

Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort studyRenate C A E van Uden, Tessa C C Jaspers, Karina Meijer, et al.

Pageof 5

Search research articles

Showing results (41-50 of 50) with videos related to

Sort By:

Pageof 5

You have reached the last page of results.This site can display upto 50 results.

Pharmacy Practice|January 15, 2019

Frequency of occurrence of medication discrepancies and associated risk factors in cases of acute hospital admissionCharlotte D Van Der Luit, Iris R De Jong, Marieke M Ebbens, et al.

Pharmacogenetics and Genomics|June 14, 2008

Pharmacy World & Science : PWS|December 26, 2006

Determinants of potential drug-drug interaction associated dispensing in community pharmacies in the NetherlandsMatthijs L Becker, Peter W J Caspers, Marjon Kallewaard, et al.

Pharmacology Research & Perspectives|July 24, 2021

Switching TNFα inhibitors: Patterns and determinantsRosanne W Meijboom, Helga Gardarsdottir, Matthijs L Becker, et al.

International Journal of Clinical Pharmacy|July 28, 2018

Development of a risk model for predicting QTc interval prolongation in patients using QTc-prolonging drugsAnita N Bindraban, José Rolvink, Florine A Berger, et al.

British Journal of Clinical Pharmacology|October 24, 2017

QTc prolongation during ciprofloxacin and fluconazole combination therapy: prevalence and associated risk factorsFlorine A Berger, Nico Monadian, Natasja M S de Groot, et al.

Pharmacogenetics and Genomics|November 23, 2013

The SLCO1B1 c.521T>C polymorphism is associated with dose decrease or switching during statin therapy in the Rotterdam StudyCatherine E de Keyser, Bas J M Peters, Matthijs L Becker, et al.

European Journal of Clinical Pharmacology|November 24, 2017

Risk factors for QTc interval prolongationCharlotte P M Heemskerk, Marieke Pereboom, Karlijn van Stralen, et al.

European Journal of Clinical Pharmacology|July 28, 2021

Unintentional guideline deviations in hospitalized patients with two or more antithrombotic agents: an intervention studyRenate C A E van Uden, Marcel P H van den Broek, Ilse Houtenbos, et al.

Thrombosis Research|February 20, 2024

Smaller nadroparin dose reductions required for patients with renal impairment: A multicenter cohort studyRenate C A E van Uden, Tessa C C Jaspers, Karina Meijer, et al.

Pageof 5